February 1, 1999Journal of Cardiovascular Electrophysiology

Current Antiarrhythmic Drugs

View Full Paper

Ask AI

Bookmark

Population

Patients with cardiac arrhythmias, particularly atrial fibrillation and ventricular arrhythmias

Design

Review

Authors

BSBramah N. SinghElectrophysiology

Discussion

Member takes

Implication

Supports shift toward beta blockers and complex Class III agents in AF; leaves open the clinical utility of multi-channel blockers like azimilide.

Structured PICO

Population

Patients with cardiac arrhythmias, particularly atrial fibrillation and ventricular arrhythmias

Intervention

Antiarrhythmic drugs (including sodium channel blockers, beta blockers, and Class III agents such as sotalol, amiodarone, dofetilide, d-sotalol, tedisamil, and azimilide)

This review outlines the evolving landscape of antiarrhythmic drug therapy, emphasizing the growing role of complex Class III agents and multi-channel blockers for atrial fibrillation.

Cite This Study

Bramah N. Singh (1999) studied this question.

synapsesocial.com/papers/6a71639ff44fa9f079df2fd0 https://doi.org/10.1111/j.1540-8167.1999.tb00674.x

View Full Paper

Ask AI

Bookmark

Implication

Supports shift toward beta blockers and complex Class III agents in AF; leaves open the clinical utility of multi-channel blockers like azimilide.

Current Antiarrhythmic Drugs

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Current Antiarrhythmic Drugs

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider